Introduction {#s1}
============

Approximately 50% of patients with uveal melanoma (UM) develop metastatic disease, which is almost always fatal. Using multivariable analysis including patient age, sex, clinical features incorporated in the tumor, node, metastasis (TNM) staging system of the American Joint Committee on Cancer, histopathology, and cytogenetics has become the gold standard for personalized survival prognostication.[@i2164-2591-8-2-18-b01][@i2164-2591-8-2-18-b02][@i2164-2591-8-2-18-b03][@i2164-2591-8-2-18-b04][@i2164-2591-8-2-18-b05]--[@i2164-2591-8-2-18-b06]

Of all predictive factors, tumor genetic information remains the most informative, with chromosome 3 loss and *BAP1* mutation, as well as class 2 gene expression profile (GEP) correlating most strongly with metastatic death.[@i2164-2591-8-2-18-b07],[@i2164-2591-8-2-18-b08] Chromosome 8 gain also confers increased mortality risk, with some studies suggesting that chromosome 3 loss and 8 gain must both be present for metastasis to occur.[@i2164-2591-8-2-18-b09],[@i2164-2591-8-2-18-b10] Chromosome 6p gain is associated with a relatively good prognosis and is rare in tumors with chromosome 3 loss. When chromosome 6p gain coexists with chromosome 3 loss, survival is better than with monosomy 3 alone.[@i2164-2591-8-2-18-b10],[@i2164-2591-8-2-18-b11]

More than 85% of UMs show *GNAQ* or *GNA11* mutation, which are mutually exclusive, initiating oncogenic events, and are, therefore, useful in differentiating UM from other lesions such as choroidal metastases.[@i2164-2591-8-2-18-b12],[@i2164-2591-8-2-18-b13] Loss-of-function mutations in the *BAP1* tumor suppressor gene on chromosome 3 are found in 49% of UM and are strongly correlated with metastasis.[@i2164-2591-8-2-18-b14] Mutations in *EIF1AX* and *SF3B1*, which also tend to occur in a mutually exclusive pattern, are associated with low and intermediate risk, respectively.[@i2164-2591-8-2-18-b15][@i2164-2591-8-2-18-b16][@i2164-2591-8-2-18-b17][@i2164-2591-8-2-18-b18]--[@i2164-2591-8-2-18-b19] Other less common UM mutations include *SRSF2*, *U2AF1*, *PLCB4*, and *CYSLTR2*.[@i2164-2591-8-2-18-b18],[@i2164-2591-8-2-18-b20],[@i2164-2591-8-2-18-b21] *CYSLTR2* and *PLCB4* occur mutually exclusively with *GNAQ* and *GNA11* as initiating oncogenic events and do not influence metastatic behavior. *SRSF2* and *U2AF1* appear to function as splicing factors akin to *SF3B1*.[@i2164-2591-8-2-18-b18]

The UCSF500 assay uses hybrid capture enrichment of target DNA to interrogate approximately 500 genes that are frequently mutated in cancers, including genes known to be altered in UM. This test also detects genome-wide chromosomal copy number changes using the off-target sequencing reads.[@i2164-2591-8-2-18-b22] It has been in clinical use at University of California, San Francisco (UCSF) since 2013 and is used for a wide variety of solid and blood cancers.[@i2164-2591-8-2-18-b23]

The aims of this study were to determine the clinical use of the UCSF500 assay in UM patients and to correlate results with known genetic, clinical, and histopathologic predictors of metastasis. It was not our intention to identify novel prognostic markers but rather to reconfirm known correlations and to determine the clinical utility of the UCSF500 assay for UM. We compared genetic alterations including prognostically relevant copy number changes of chromosomes. Chromosome 3 loss (a metastasis predictor) was correlated with known genetic aberrations in UM, such as *GNAQ*, *GNA11*, *SF3B1*, *EIF1AX*, and *BAP1* mutations, GEP class, and with established clinical and histopathologic parameters associated with metastatic risk. Results here are based on our experience using the UCSF500 for UM since 2013, with preliminary findings presented in 2016.[@i2164-2591-8-2-18-b24] To our knowledge, this is the first study to report both next-generation sequencing (NGS) and GEP results in a cohort of UM patients.

Methods {#s2}
=======

Patients {#s2a}
--------

The 62 patients in this study were recruited prospectively from the UCSF Ocular Oncology Service, starting in August of 2013. Patients were included if treated with proton beam radiotherapy, plaque brachytherapy, enucleation, or endoresection. They were excluded if they had received prior radiotherapy, in case radiotherapy might have influenced genetic testing results. Four patients who were invited to participate in the study declined to have any genetic testing of their tumors. This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines, under the approval of the UCSF Institutional Review Board (CC number 14852). Consent for the use of tissues and data for research was obtained from all patients.

Clinical Methods {#s2b}
----------------

Clinical evaluation included full ophthalmologic examination and measurement of largest basal tumor diameter and tumor thickness by B-scan echography (Eyecubed; Ellex, Adelaide, Australia). Systemic clinical examination was performed in a routine manner with abdominal magnetic resonance imaging performed both with and without contrast at time of diagnosis and every 6 months thereafter. Postoperatively, patients were referred to a medical oncologist for systemic screening.

Tumors were categorized as involving ciliary body if they extended anterior to ora serrata. Extraocular extension was recorded as being present if this was noted clinically or histopathologically.

Tumor Sampling {#s2c}
--------------

Tumors treated by proton beam radiotherapy or brachytherapy were sampled by transscleral fine-needle aspiration or transretinal vitrector biopsy[@i2164-2591-8-2-18-b25] (25- or 27-gauge). All biopsies were performed prior to radiation at the time of tantalum marker or plaque insertion. For eyes undergoing enucleation or endoresection, a fresh tumor sample was obtained at the time of surgery. Tissue samples were provided to the UCSF Clinical Cancer Genomics Laboratory for DNA extraction, library preparation, and sequencing and to Castle Biosciences (Friendswood, TX) for GEP.

Histopathologic Examination {#s2d}
---------------------------

The diagnosis of melanoma was confirmed by light microscopy on sections stained with hematoxylin and eosin and, if necessary, by Melan A immunohistochemistry. Melanoma cells were categorized as spindle, epithelioid, or mixed, according to the modified Callender system.[@i2164-2591-8-2-18-b26] For statistical analysis, tumors were dichotomized as either having no epithelioid cells (spindle cell morphology) or having the presence of any epithelioid cells (mixed or epithelioid morphology).

Genetic Analysis {#s2e}
----------------

### Next-Generation Sequencing {#s2e1}

The UCSF500 assay was performed at the UCSF Clinical Cancer Genomics Laboratory. This assay uses solution phase hybrid capture using a custom bait library (NimblegenSeqCap)[@i2164-2591-8-2-18-b27] of 2.8 Mbp of genomic sequence and includes all exons of approximately 500 cancer-related genes and selected introns of 40 of these genes. In addition, the assay captures 2,000 unique sequences containing common single nucleotide polymorphisms within regions devoid of constitutional copy number variations to assist in genome-wide copy number and allelic imbalance analysis.

Barcoded samples were pooled, and captured libraries were sequenced with a read length of 100 nucleotides from both directions at \>500-fold coverage on a single lane of an Illumina HiSeq 2500 instrument. Duplicate sequencing reads were removed computationally to allow for accurate allele frequency determination and copy number calling. The analysis was based on the human reference sequence UCSC build hg19 (NCBI build 37) by using the following software packages: BWA, 0.7.10-r789; Samtools, 1.1 (using htslib 1.1); Picard tools, 1.97 (1504); GATK, 2014.4-3.3.0-0-ga3711; CNVkit, 0.3.3; Pindel, 0.2.5a7; SATK, 2013.1-10-gd6fa6c3; Annovar, v2015Mar22; Freebayes, 0.9.20; and Delly, 0.5.9. Copy number changes were calculated from on- and off-target reads using CNVkit.[@i2164-2591-8-2-18-b22],[@i2164-2591-8-2-18-b28][@i2164-2591-8-2-18-b29][@i2164-2591-8-2-18-b30][@i2164-2591-8-2-18-b31][@i2164-2591-8-2-18-b32][@i2164-2591-8-2-18-b33][@i2164-2591-8-2-18-b34][@i2164-2591-8-2-18-b35][@i2164-2591-8-2-18-b36]--[@i2164-2591-8-2-18-b37]

### Gene Expression Profiling {#s2e2}

Tumor samples were immediately placed after biopsy or harvesting in provided fixative and packed with dry ice and sent to Castle Biosciences for gene-expression profiling, with methods as previously reported.[@i2164-2591-8-2-18-b08]

Statistical Analysis {#s2f}
--------------------

All data analyses were performed using the R statistical language.[@i2164-2591-8-2-18-b38] To test associations between chromosome 3 loss and other clinical and other genetic factors, the exact Wilcoxon rank sum test[@i2164-2591-8-2-18-b39] and the Fisher\'s exact test were used for continuous and categorical variables, respectively. The odds ratios and corresponding confidence intervals were estimated using the fisher.test function.

All categorical variables were dichotomized except for TNM stage, which was grouped into four levels: T1, T2, T3, and T4. The Cochrane-Armitage test[@i2164-2591-8-2-18-b38] was used to test for trend of TNM stage with chromosome 3 status. All tests were two-sided, with *P* values less than 0.05 regarded as significant. Kaplan-Meier curves were plotted. The log-rank test was performed to demonstrate associations between metastasis-free survival and chromosome 3 loss, chromosome 8q gain, *BAP1* mutation, and GEP class.

Results {#s3}
=======

Patient Demographics {#s3a}
--------------------

Of the 62 patients, 36 were male and 26 were female. Fifty-three patients were white, 6 were Asian, and 3 patients were Hispanic ([Table 1](#i2164-2591-8-2-18-t01){ref-type="table"}). The mean age was 58.56 years (SD, 13.24; range, 24--89 years).

###### 

Patient Demographics, Tumor Clinical Features, TNM Stage, and Treatment^a^

  Patient Information                     Value, *N* = 62
  ---------------------------------- --------------------------
  Demographics                       
   Mean age (median, range), years    58.65 (58, 24.00--89.00)
   Sex                               
    Male                                      35 (57)
    Female                                    26 (43)
   Race                              
    White                                     53 (85)
    Asian                                      6 (10)
    Hispanic                                   3 (5)
  Tumor clinical features            
   Affected eye                      
    Right                                     38 (61)
    Left                                      24 (39)
   Location                          
    Choroidal                                 54 (87)
    Ciliary body                               3 (5)
    Ciliochoroidal                             5 (8)
    Extraocular extension                      3 (5)
  TNM stage (all N0M0)               
   T1                                         18 (29)
    T1a                                          17
    T1b                                          1
   T2                                         19 (31)
    T2a                                          18
    T2b                                          1
   T3                                         19 (31)
    T3a                                          18
    T3b                                          1
   T4                                          6 (10)
    T4b                                          3
    T4c                                          3
  Ophthalmic treatment               
   Proton beam radiotherapy                   34 (55)
   Enucleation                                18 (29)
   Local resection                             8 (13)
   Plaque brachytherapy                        2 (3)

Values shown are number (nearest %) except where indicated.

Baseline Study Eye Characteristics {#s3b}
----------------------------------

The tumors involved the right eye in 38 patients and the left eye in 24, with ciliary body involvement in 8 patients, and extraocular extension in 3. The mean largest basal tumor diameter was 11.94 mm (range, 4.80--20.00) and the median tumor thickness was 5.65 mm (range, 0.69--16.00). The TNM stage was T1 in 18 patients, T2 in 19, T3 in 19, and T4 in 6 ([Table 1](#i2164-2591-8-2-18-t01){ref-type="table"}). All were N0M0 at diagnosis.

Histopathologic and Genetic Results {#s3c}
-----------------------------------

The laboratory results are summarized in [Figure 1](#i2164-2591-8-2-18-f01){ref-type="fig"}. The tumors were classified as spindle cell in 25 patients, epithelioid in 15, and mixed in 19. Histology was inconclusive in three patients, because of pauci-cellular samples.

![Tiling plot including clinical, histopathologic, and genetic features for all patients.](i2164-2591-8-2-18-f01){#i2164-2591-8-2-18-f01}

### Next-Generation Sequencing {#s3c1}

Chromosome 3 loss (monosomy 3) was seen in 30 (48%) tumors, with 5 of these showing partial loss of chromosome 3. Chromosome 8q gain and 6p gain were seen in 32 (52%) and 21 (34%) tumors, respectively. Genome-wide copy chromosomal copy number changes in two representative cases are shown in [Figure 2](#i2164-2591-8-2-18-f02){ref-type="fig"}. *GNAQ* and *GNA11* mutations were present in 36 (58%) and 26 (42%) tumors, respectively, and were mutually exclusive. *BAP1* inactivating mutations were present in 23 (37%) patients. *SF3B1* mutations and *EIF1AX* mutations were detected in 19 (31%) and 8 (13%) tumors, respectively. No tumors had *SRSF2*, *U2AF1*, or *PLCB4* mutations.

![Genome-wide copy number profiles for two representative cases. Shown are the raw log2 ratios of the normalized bin counts from CNVKit (y-axis) along genomic coordinates (x-axis) with segments obtained by circular binary segmentation (black lines) Top: Copy number alterations include losses of chromosomes 3, 8p, and 16q and gain of 8q in a UM that also carried a GNAQ p.Q209P and a truncating BAP1 p.Q4\* mutation. Bottom: Copy number gains of 6p and 21 in a tumor with an GNAQ p.Q209L mutation.](i2164-2591-8-2-18-f02){#i2164-2591-8-2-18-f02}

### Gene Expression Profiling {#s3c2}

Of the 62 tests performed by Castle Biosciences, three were categorized as "technical failure." In five patients, GEP was not performed. This was because of transport problems in one case, with two patients declining Castle testing, and two samples (both from tumors \<1 mm thick) considered too small for both types of genetic analysis so that only UCSF500 was performed.

Treatment {#s3d}
---------

Treatment consisted of proton beam radiotherapy in 34 patients, enucleation in 18, endoresection in 8, and plaque brachytherapy in 2 patients ([Table 1](#i2164-2591-8-2-18-t01){ref-type="table"}).

Biopsy Technique {#s3e}
----------------

Transretinal biopsy (either with vitrector after tantalum marker insertion or during endoresection) was performed in 36 patients and transscleral fine-needle aspiration in 8, with tumor harvesting after enucleation in 18 patients.

Correlation of Genetic Alterations With Predictors of Metastasis {#s3f}
----------------------------------------------------------------

UCSF500 results and clinical and histopathologic features are presented in [Figure 1](#i2164-2591-8-2-18-f01){ref-type="fig"} and [Table 2](#i2164-2591-8-2-18-t02){ref-type="table"}.

###### 

Tumor Histology and Genetics

  Variable                                          Value, *N* (%)
  ------------------------------------------------ ----------------
  Histology, *N* = 59                              
   Spindle cell                                        25 (42)
   Epithelioid                                         15 (25)
   Mixed                                               19 (32)
  Genetics---UCSF500, *N* = 62                     
   Mutations of relevance                          
  *  GNAQ*                                             36 (58)
  *  GNA11*                                            26 (42)
  *  SF3B1*                                            19 (31)
  *  EIF1AX*                                            8 (13)
  *  BAP1*                                             23 (37)
   Chromosomal aberrations                         
    Chromosome 1 loss                                  14 (23)
    Chromosome 3 loss (any)                            30 (48)
    Chromosome 3 loss (partial)                         5 (8)
    Chromosome 6 gain                                  21 (34)
    Chromosome 8 gain                                  32 (52)
  Genetics---gene expression profiling, *N* = 54   
   Class 1A                                            21 (39)
   Class 1B                                            13 (24)
   Class 2                                             20 (36)
   Test result of technical failure                     3 (37)
   Test not done (UCSF500 done only)                      5

The associations between chromosome 3 loss (partial or total) and clinical, histopathologic, and other genetic alterations are presented in [Table 3](#i2164-2591-8-2-18-t03){ref-type="table"}. Chromosome 3 loss was more frequent in tumors with larger basal diameter (Wilcoxon rank sum test, *P* = 0.015), greater thickness (*P* = 0.016), more advanced TNM stage (*P* = 0.006), presence of any epithelioid cells (*P* \< 0.001), *BAP1* mutation (*P* \< 0.001), and chromosome 8q gain (*P* \< 0.001). There was no statistically significant association found between chromosome 3 loss and the mutational status of *GNAQ* (*P* = 0.200), *GNA11* (*P* = 0.200), or *SF3B1* (*P* = 0.280). An inverse association was seen between chromosome 3 loss and chromosome 6p gain (*P* \< 0.001).

###### 

Association of Clinical and Genetic Variables With Chromosome 3 Loss^a^

  Variable                               *P* Value     OR           95% CI
  -------------------------------------- ------------- ------------ ---------------------------
  Clinical features                                                 
  ** Largest basal diameter**            **0.015**     **N/A**      
  ** Thickness**                         **0.016**     **N/A**      
  ** TNM stage**                         **0.006**     **N/A**      
  ** Epithelioid cells (any)**           **\<0.001**   **19.07**    **(4.30--123.20)**
   Ciliary body involvement              0.131         3.96         (0.63--43.55)
   Extraocular extension                 0.097         ∞            (0.48--∞)
  Genetics---UCSF500                                                
   Mutations of relevance                                           
  *  GNAQ*                               0.198         0.47         (0.15--1.46)
  *  GNA11*                              0.198         2.12         (0.68--6.79)
  *  SF3B1*                              0.409         0.56         (0.16--1.91)
  *  EIF1AX*                             0.054         0.14         (0.003--1.18)
  ***  BAP1***                           **\<0.001**   ∞            **(21.75--∞)**
   Chromosomal aberrations                                          
    Chromosome 1 loss                    0.544         1.70         (0.44--6.95)
  **  Chromosome 6 gain**                **\<0.001**   **0.15**     **(0.03**--**0.59)**
  **  Chromosome 8 gain**                **\<0.001**   **35.51**    **(7.60**--**244.70)**
  Genetics---gene expression profiling                              
  ** Class 2 vs. class 1**               **\<0.001**   **120.80**   **(13.65**--**5,905.96)**

Significant associations are in bold. OR, odds ratio; CI, confidence interval; N/A, not applicable.

Class 2 GEP tumors were much more likely to have chromosome 3 loss than class 1 GEP tumors (odds ratio 121, *P* = 6.2 × 10^−10^).

Association With Metastasis-Free Survival {#s3g}
-----------------------------------------

The median metastasis-free survival time was 27 months (range, 6--60). Metastatic disease developed in 11 (18%) patients, 5 (8%) of whom died. All patients with metastases had chromosome 3 loss, chromosome 8q gain, *BAP1* mutation, and class 2 GEP. Chromosome 3 loss (*P* = 6.54 × 10^−5^) alone and combined chromosome 3 loss, chromosome 8q gain, and *BAP1* mutation (*P* = 5 × 10^−7^) were associated with metastatic disease. Kaplan-Meier curves ([Figure 3](#i2164-2591-8-2-18-f03){ref-type="fig"}) show that the median survival was 37 months in patients whose tumors showed chromosome 3 loss and 35 months in patients whose tumor showed combined chromosome 3 loss, chromosome 8q gain and *BAP1* mutation (log rank test, *P* \< 0.001).

![Kaplan-Meier curves demonstrating time to metastasis. Top: Time to metastasis in patients according to chromosome 3 loss, detected with the UCSF500 assay. Middle: Time to metastasis in patients with combination of chromosome 3 loss, 8 gain and BAP1 mutation, and time to metastasis with at least one of these three genetic features absent. Bottom: Time to metastasis in patients according to GEP class (class 1 vs. class 2).](i2164-2591-8-2-18-f03){#i2164-2591-8-2-18-f03}

Discussion {#s4}
==========

Main Findings {#s4a}
-------------

Genetic predictors for metastasis that were detected with the UCSF500 assay correlated closely with clinical and histologic risk factors, as well as GEP results. The UCSF500 assay had a low failure rate, even with small tumor biopsy samples, providing meaningful genetic results in all 62 patients tested. Its deployment was straightforward in routine clinical practice.

Discussion of Methods {#s4b}
---------------------

Targeted sequencing of DNA can detect multiple types of genetic alterations, including single nucleotide variants, small insertions/deletions, structural rearrangements, and copy number alterations, thereby providing a richer view of relevant genetic alterations compared to fluorescence in situ hybridization and single gene sequencing.[@i2164-2591-8-2-18-b02] The method is quantitative and sensitive enough to detect melanoma mutations, even in the presence of a considerable fraction of stromal cells. The low complexity of the genetic landscape of UMs with highly recurrent mutations at hotspots of a few genes allows for accurate quantitation of tumor fractions, providing a potential advantage over gene expression analyses.

An additional advantage of UCSF500 is its ability to confirm that the biopsy specimen is of uveal melanocytic origin, by detecting *GNAQ* and *GNA11* mutations. The richness of molecular data provided by the UCSF500 may assist in diagnostic accuracy for other tumors. In a recent study using the UCSF500 in pediatric neurooncologic patients, the diagnosis of six tumors (19%) was revised after genomic profiling, including high-grade glioma to pilocytic astrocytoma, medulloblastoma to pineoblastoma, ependymoma to high-grade glioma, and medulloblastoma to central nervous system high-grade neuroepithelial tumor with BCOR alteration.[@i2164-2591-8-2-18-b23]

An advantage of this pancancer assay is also that genetic mutations of relevance to a variety of cancers can also be added to the assay as new discoveries are made. The version of the assay in this study investigated mutations in *GNAQ*, *GNA11*, *SF3B1*, *EIF1AX*, *BAP1*, and *PCLB4*. Since the study, *U2AF1* and *CYSLTR2* have been added. In addition, although all sequencing was performed on fresh tumor specimens, the UCSF500 assay can also be used to analyze formalin-fixed, paraffin-embedded tissue,[@i2164-2591-8-2-18-b23] although this was not needed in this study because fresh samples were available for all patients.

Discussion of NGS Results {#s4c}
-------------------------

The association of genetic alterations, as detected with NGS, with known predictors of metastasis, listed in [Table 3](#i2164-2591-8-2-18-t03){ref-type="table"}, are in keeping with the published literature. Chromosome 3 loss was associated with *BAP1* mutation, chromosome 8q gain, largest basal tumor diameter, tumor thickness, TNM stage, and presence of epithelioid cells.[@i2164-2591-8-2-18-b01],[@i2164-2591-8-2-18-b08],[@i2164-2591-8-2-18-b09],[@i2164-2591-8-2-18-b40],[@i2164-2591-8-2-18-b41] As anticipated, chromosome 3 loss was inversely associated with chromosome 6p gain.[@i2164-2591-8-2-18-b09],[@i2164-2591-8-2-18-b15],[@i2164-2591-8-2-18-b16],[@i2164-2591-8-2-18-b17],[@i2164-2591-8-2-18-b18] No *PCLB4*, *SRF2*, or *U2AF1* mutations were identified. Although *CYSLTR2* was not included in the UCSF500 at the time of the study, all tumors sequenced had *GNAQ* and *GNA11* mutations. Because *CYSLTR2* is mutually exclusive of these mutations, it is unlikely the lack of the gene in the assay affected study results.[@i2164-2591-8-2-18-b21]

As expected, all 11 tumors that metastasized during the study period had chromosome 3 loss, chromosome 8q gain, *BAP1* mutation, and class 2 GEP.[@i2164-2591-8-2-18-b09],[@i2164-2591-8-2-18-b11],[@i2164-2591-8-2-18-b41] Interestingly, the combination of chromosome 3 loss and chromosome 8 gain has also been shown to confer increased metastatic risk in oral cancer.[@i2164-2591-8-2-18-b42]

No significant association between *SF3B1* mutation and chromosome 3 loss was seen. There is a lack of consensus on the prognostic value of the *SF3B1* mutation, with some reports indicating lower metastatic risk[@i2164-2591-8-2-18-b15],[@i2164-2591-8-2-18-b16],[@i2164-2591-8-2-18-b18],[@i2164-2591-8-2-18-b43] and another indicating potentially increased risk of late metastasis.[@i2164-2591-8-2-18-b19] Longer-term follow up will be needed to determine the prognostic relevance of *SF3B1* mutations.

The tissue sample was sufficient for NGS in all 62 tumors. Six of these tumors were less than 2 mm in thickness, with two less than 1 mm in thickness (i.e., 0.69 mm and 0.74 mm, respectively). Although the histopathology was interpreted as inconclusive due to paucicellular sample in three of these cases, NGS identified *GNAQ* or *GNA11* mutations in all of these, providing evidence that the neoplasms were of melanocytic lineage. In two of these tumors with inconclusive histology, NGS also confirmed malignancy by identifying chromosome 6p gain in one tumor and *SF3B1* mutation, loss of chromosome 1p, partial chromosome 3 deletion, and chromosome 8q gain in the other tumor. The third tumor in which histology failed was 8.80 mm thick and sampled transsclerally by fine-needle aspiration biopsy. The specimen was inadequate for histology probably because too much was used for genetic studies. In any case, NGS provided a diagnosis of melanoma by demonstrating *GNA11* and *SF3B1* mutations as well as chromosome 6p gain.

NGS Versus GEP {#s4d}
--------------

Notably, there was concordance between GEP class and NGS sequencing result in all class 2 tumors, which showed loss of chromosome 3 (*P* = 6 × 10^−10^) and the majority (18 of 21 class 2 tumors) had chromosome 8 gain. Surprisingly, 4 of 20 (20%) class 1A tumors and 1 of 13 (8%) class 1B tumors showed chromosome 3 loss. Of these class 1 tumors with chromosome 3 loss, only one patient had true monosomy 3; the other four patient specimens demonstrated partial/focal loss of chromosome 3, sparing the *BAP1* locus. Long-term follow up is needed to determine if partial chromosome 3 loss will lead to increased metastatic risk in these patients.

Strengths and Weaknesses of Study {#s4e}
---------------------------------

Strengths of this study are the prospective data collection and the large number of patients. The main weakness is the short follow up, which resulted in few patients with metastatic disease and prediction of time to metastasis.

Comparison With Other Studies {#s4f}
-----------------------------

The results obtained with NGS in this study are comparable to those reported with microsatellite analysis, fluorescence in situ hybridization, GEP, and other genetic methods used to analyze UM.[@i2164-2591-8-2-18-b01],[@i2164-2591-8-2-18-b02],[@i2164-2591-8-2-18-b08],[@i2164-2591-8-2-18-b09],[@i2164-2591-8-2-18-b43],[@i2164-2591-8-2-18-b44] A study by Smit et al.[@i2164-2591-8-2-18-b45] demonstrated that an NGS kit developed in Rotterdam, The Netherlands, specifically for UM showed concordant results with other methods of genetic analysis.[@i2164-2591-8-2-18-b45] This was done with a bank of carefully selected specimens and not in routine clinical practice, unlike our study. The Rotterdam panel analyzed 98 amplicons, which included 17 amplicons covering highly polymorphic regions in chromosomes 1 and 8, and 21 amplicons on chromosome 3, with the remainder covering all exons on the *BAP1* gene and the exons containing known mutation hotspots on *GNAQ*, *GNA11*, *EIF1AX*, and *SF3B1*. In comparison, the UCSF500 assay provides substantially higher resolution of copy number changes; it uses hybrid capture rather than polymerase chain reaction amplification for enrichment, providing a more accurate assessment of copy number alterations.[@i2164-2591-8-2-18-b22] Although the preferred input for UCSF500 extracted from formalin-fixed paraffin-embedded tissue is 100 ng to yield a median coverage of 200 or more unique sequence reads, it can reliably detect UM typical alterations in unfixed samples with 10 ng of input material or less.

Conclusions {#s4g}
-----------

When used in routine clinical practice, the UCSF500 test successfully identifies known genetic predictors of metastasis in UM.

The strong concordance between UCSF500 results and known genetic, clinical, and histopathologic predictors suggests that the UCSF500 assay is a useful prognostic test in patients with UM. As with other genetic methods, the NGS results only indicate whether the UM is likely to have metastasized; multivariate analysis that includes anatomic, histopathologic, and genetic predictors is required to provide more accurate assessment of an individual patient\'s life expectancy.[@i2164-2591-8-2-18-b46]
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